challenge of DBA/2 mice with 10 s 1A1 or 105 1A1-G3AF7 cells on day 0. Mice were treated intraperitoneally on days 1, 3, 7, and 10 with 0.1 ml of ascites fluid from mice bearing hybridoma cells that produce monoclonal IgG3 anti-asialo GM2 (3 mg antibody per ml of pooled ascites fluid). Due to lethal Sendai virus infections of DBA/2 mice in our mouse colony, the identical serotherapy protocol was also conducted in CD2. F1 mice.
Karyotype Analysis. Chromosome preparations were made as described by Miller et al. (6) .
This method has been used previously for the analysis of other L5178Y lymphoma variants (7) .
Effector Cells. The source of natural killer (NK) cells was the spleens of adult CBA mice that had received 100/~g poly I:C (Sigma Chemical Co., St. Louis, MO) intraperitoneally in 0.1 ml RPMI 1640 1 d earlier.
Microcytotoxicity Assays. Target cells were 5~Cr labeled as previously described (8) , assays were performed in V-bottomed microtiter plates (Linbro Scientific, Hamden, CT), and all dilutions were made with RPMI containing i0% newborn calf serum (Sterile Systems, Logan, UT). For antibody-complement assays, each well received 0.05 ml antiserum, 0.05 ml of a 1:8 dilution of either native or heated (56°C, 30 rain) English smooth hair guinea pig serum as a complement source, and 0.1 ml containing 2 X 104 labeled target cells. Plates were incubated for 45 rnin at 37°C, centrifuged at 250 g for I rain, and 0.1 ml of the cell-free supernatant was measured for ~ICr content in a gamma scintillation counter.
For NK cell assays, effector cells and 2 × 104 ~XCr-labeled target cells were combined in a total volume of 0.2 ml per well. The plates were centrifuged at 250 g for 1 min both before and after a 4-h incubation at 37°C, and then 0.1 ml of the supernatant was assayed for SICr content.
Specific lysis was calculated relative to the spontaneous release observed in wells containing target cells alone according to the following equation: percent specific lysis = ([test cpmspontaneous cpm]/[cpm released by three cycles of freeze-thaw]) × 100. Freeze-thawed cells released ~80% of their total radioactivity.
Flow Microfluorometry. Cells were washed twice and then incubated for 60 min at 4°C with a 1:10 dilution of mouse IgM anti-asialo GM2 ascites fluid that had been heated at 56 °, 30 min d or a 1:25 dilution of anti-H2 serum (NIH serum D-13). After three washes, the cells were incubated for 60 min at 4°C with a 1:50 dilution of fluorescein-labeled goat anti-mouse immunoglobulin (N. L. Cappel Laboratories, Cochranville, PA). After two washes, the cells were analyzed on a fluorescence-activated cell sorter (FACS IV; B-D FACS Systems Becton, Dickinson & Co., Sunnyvale, CA).
Results
Cytogenetic Analysis. As previously described (3), serotherapy with IgG3 anti-asialo GM2 protected the majority of mice from challenge with an asialo GM2-positive variant (1A1) of L5178Y lymphoma cells. However, in a few cases asialo GM2-deficient ascites tumor cells arose after a prolonged period (3) . To determine whether these ascites tumor cells were progeny of the ceils used for initial challenge rather than having been newly induced in the host, we searched for abnormal chromosomal markers common to both original and emergent cells.
The original 1A1 cells used for challenge as well as the cells derived from two antibody-treated mice had more than the diploid number of chromosomes, often about 50 60 chromosomes per cell. These included copies of normal chromosomes, as well as structurally altered or marker chromosomes. Fig. 1 demonstrates that several marker chromosomes were found to be common to all three cell lines. These results indicate that these lines were closely related and strongly suggest that the cells arising after antibody treatment were progeny of the original 1A1 cell inoculum.
Antigen Display on Lymphoma Variants. Flow microfluorometry was used to examine the display of asialo GM2 and H-2 a on 1Al and ascites tumor cells derived from untreated and anti-asialo GM2-treated mice (Fig. 2) . All cell lines were cultured in vitro for at least 1 mo before analysis to eliminate both host cells and residual The largest marker is a biarmed chromosome that includes two copies of the X (probably plus some duplicated material). The third largest is a chromosmne in which both arms are copies of number 10. Tim sixth and seventh chromosomes from the left are identical; they are copies of number 2 with an elongated centron, eric region. Tbe eighth and ninth from the left are again identical representing a number 11 with material added to the distal end. a n t i b o d y that could h a v e c o v e r e d or m o d u l a t e d t u m o r cell surface d e t e r m i n a n t s . In contrast to the u n i f o r m , positive reaction o f 1A1 cells with anti-asialo G M 2 , < 5 % of cells from a n t i b o d y -t r e a t e d m i c e ( 1 A 1 -G 3 A F 7 , 1A1-616, a n d 1AI-1010) d i s p l a y e d detectable asialo G M 2 . Interestingly, cells from u n t r e a t e d mice r e p r e s e n t e d a m i x t u r e of asialo G M 2 -p o s i t i v e a n d -negative cells; 49% of I A I -T U cells a n d 25% o f 1A 1-245 cells reacted with anti-asialo G M 2 . U n l i k e the d r a m a t i c alterations in asialo G M 2 display, the expression of H-2 a on these cell lines was virtually u n c h a n g e d from that of 1A1 cells. T h u s , in vivo passage of 1A1 cells a p p e a r e d to result in selection of cells deficient in asialo G M 2 but not H-2 a d e t e r m i n a n t s , p a r t i c u l a r l y in m i c e t r e a t e d with anti-asialo G M 2 (see Discussion).
T o d e t e r m i n e the stability o f a s i a l o G M 2 display on the cells d e r i v e d from u n t r e a t e d mice, 1 A 1 -T U cells were stained with anti-asialo G M 2 a n d then sorted on the flow c y t o m e t e r to separate asialo G M 2 -p o s i t i v e a n d -negative populations. T h e s e cells were r e t u r n e d to culture for 10 d a n d then r e a n a l y z e d for asialo G M 2 expression. Fig. 3 indicates that each p o p u l a t i o n r e t a i n e d its original asialo G M 2 display a n d thus represented stable subsets of cells with regard to asialo G M 2 expression.
T h e cell variants were also c o m p a r e d for their susceptibility to a n t i b o d y -c o m p l em e n t -m e d i a t e d lysis. T h e purpose of this e x p e r i m e n t was not only to o b t a i n a d d i t i o n a l e v i d e n c e r e g a r d i n g the a n t i g e n i c display of these cells, but also to d e t e r m i n e their sensitivity to lyric effector m e c h a n i s m s . I g M anti-asialo G M 2 ascites fluid was used for this assay rather than the IgG3 ascites because the former had a titer for c o m p l e m e n t -d e p e n d e n t cell lysis 10,000-fold higher than the latter. T h e results of lysis by anti-asialo G M 2 plus complement (Table I) were consistent with the flow microfluorometry data. Cells from a n t i b o d y -t r e a t e d mice (1A1-G3AF7, 1A1-616, and 1Al-l010) were highly resistant, whereas lysis of the two cell lines from untreated mice (1A1-TU and 1A1-245) roughly corresponded to the percentage of positive cells determined by cell sorter analysis (Fig. 2) . However, the level of a n t i b o d y required to achieve m a x i m a l lysis suggested that the cells from untreated mice might be more resistant to the action of c o m p l e m e n t than 1A1 cells. A comparison of the variants with regard to the effect of anti-H-2 d serum revealed an a p p r o x i m a t e l y two-to fourfold difference in sensitivity to c o m p l e m e n t -m e d i a t e d cytolysis (Table I ). These differences a p p e a r e d to be unrelated to the origin of each cell line; of the three cell lines from a n t i b o d y -t r e a t e d mice, one (1A1-G3AF7) was highly sensitive, whereas the other two (1A1-616 and 1AI-1010) were much more resistant. As H-2 a expression determined by flow cytometry was virtually identical among the variants (Fig. 2) , these results suggested differences in susceptibility to c o m p l e m e n t action.
Susceptibility to NK Cell Attack. Variants of L5178Y cells have been shown to differ
in their susceptibility to N K cell lysis (4, 8, 9) . T h e possibility existed, therefore, that the cells that eventually arose in a few a n t i b o d y -t r e a t e d mice might have been able to proliferate because they could resist N K cell attack. T a b l e II indicates that these cell lines were only slightly less sensitive to N K cell lysis than the highly sensitive 1A1 cells. 
Resistance of Emergent Cells to Serotherapy.
T h e d a t a described above suggest that the ascites cells that eventually arose in mice after 1A 1 cell challenge and anti-asialo G M 2 effect on survival of these mice (Fig. 4) , indicating that these cells were able to proliferate despite the immune pressures present in antibody-treated mice.
Discussion
Considerable effort is presently being devoted to the production of monoclonal antibodies directed against human tumor-associated cell surface markers. Several of these antibodies have been found to react with specific glycolipids (10 13). These antibodies may prove useful not only for cancer diagnosis but also therapy (1). An obvious limitation of such specific serotherapy would be the appearance of antigennegative tumor cells, which could avoid treatment. The generation of such variants is a predictable and essential element in the phenomenon of tumor progression (14) by which cancer cells are able to evade any selective pressure. Thus, it was not surprising that we detected asialo GM2 deficient variants arising in a few of the mice that had been challenged with 1A1 cells and treated with monoclonal IgG3 antiasialo GM2 (3) . Similarly, Bernstein and Nowinski (15) found Thy-l.l-negative leukemia cell variants in mice that had been challenged with Thy-l.l-positive leukemia cells and treated with anti-Thy-1.1-specific monoclonal antibodies.
The unexpected finding of the present study was the appearance of asialo GM2-deficient tumor cells in mice that had not been treated with anti-asialo GM2 (1AI-TU and 1A1-245 cells; Fig. 2 ). Other groups have described alterations in tumor antigen expression that were due to shielding of cell surface determinants by other macromolecules (16, 17) . This phenomenon is unlikely in our system because H-2 antigen display on the variants was unchanged (Fig. 2) and the chemical quantity of asialo GM2 on 1A1-TU cells, about half that of 1A1 cells (3), matched the percentage of cells that were reactive with anti-asialo GM2 (Fig. 2) . During in vitro culture for >2 roD, >96% of 1A 1 ceils remained asialo GM2 positive as deterrnined by cell sorter analysis. The expansion of asialo GM2-deficient cells during a similar period of time in vivo must have been the result of selective pressure. The selection process was specific, in that H-2 antigen expression was unchanged on the variants; thus, asialo GM2-negative cells may be the product of a host immune response against the glycolipid. We are currently attempting to detect such a response. Our preliminary results indicate that whereas CD2.F1 mice can be immunized to produce anti-IA1 cell antibodies, none of those antibodies is specific for asialo GM2 (unpublished observation). Alternatively, the selective pressure may have been directed against a complex of membrane determinants. It is unlikely that such a complex was the result of viral contamination, because the subclone 1A 1 cells tested negative in a screening for 12 viral contaminants including Sendai virus (data not shown).
The tumor cells that emerged from both antibody-treated and untreated mice were only slightly less sensitive to NK cell attack than 1A 1 cells (Table II) , suggesting that resistance to NK lysis was not a critical element in the phenotype of the cells that survived. However, it is possible that NK cells may act in concert with more specific immune mechanisms to decrease the tumor load. In fact, Kawase et al. (9) recently reported that modulation of NK activity effected the tumorigenicity of other L5178Y subclones.
Weinhold et al. (18) described a tumor dormant state established in L5178Y immunized and challenged mice in which a prolonged period of clinical normalcy was followed by rapid tumor outgrowth. Cytotoxic T cells reactive with L5178Y ceils were detectable during the early period of tumor dormancy. The tumor cells that eventually emerged expressed eightfold less serologically detectable tumor associated antigens than the original cells used for challenge. Our serotherapy system may have similar antitumor mechanisms at work that are directed against a battery of tumorassociated antigens, perhaps including asialo GM2. These host defenses, when combined with additional anti-tumor effects mediated by IgG3 anti-asialo GM2, may be sufficient to eradicate the tumor completely in the majority of mice.
Summary
Mice challenged with L5178Y lymphoma cells expressing high levels of the glycolipid asialo GM2 (gangliotriosylceramide) were protected from tumor growth by passive administration of a monoclonal antibody specific for the glycolipid; in a few antibody-treated mice, ascites cells eventually proliferated which contained a reduced chemical quantity of the glycolipid antigen (3). We now report that the cells emerging from antibody-treated mice had abnormal marker chromosomes identical to those in the cells used for challenge, indicating that the emergent cells were progeny of the challenge inoculum. Flow cytometric analysis revealed that asialo GM2 was undetectable on the surface of >95% of the tumor cells from antibody-treated mice, whereas surface display of H-2 determinants was unchanged from that of the cells used for challenge. Tumor cells arising in challenged but untreated mice consisted of a mixture of asialo GM2-positive and -negative cells, indicating the presence of selective pressures in these mice as well. None of the cells taken from tumor bearing mice differed significantly from the challenge cells in their susceptibility to natural killer cell attack, suggesting that resistance to natural killer cell lysis was not responsible for the proliferation of these cells in vivo.
When cells derived from an antibody-treated mouse were used to challenge mice, serotherapy with anti-asialo GM2 had no effect on mouse survival. These results suggest that serotherapy may complement a host anti-tumor response, from which only asialo GM2 deficient cells can escape.
